 |
|
|
| |
In Vitro Resistance Profile of GS-6207, a First-in-Class Picomolar HIV Capsid Inhibitor in Clinical Development as a Novel Long-Acting Antiretroviral Agent
|
| |
| |
IAS: Sharp Drops in HIV Load After 10 Days of Capsid Inhibitor Monotherapy - (07/25/19)
IAS: Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV - (07/25/19)
Reported by Jules Levin
IAS 2019 July 21-24 Mexico City
Stephen R. Yant1, Andrew Mulato1, Derek Hansen1, Alexander Thielen2, Scott D. Schroeder1, Danielle Porter1, Kirsten White1, Martin Däumer2, Winston C. Tse1 and Tomas Cihlar1
1Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA, 94404, USA; 2Seq-IT GmbH & Co.KG, Pfaffplatz 10, Kaiserslautern, 67655, Germany
|
| |
|
|
|
|
|
